Available Clinical Trials

To inquire about participating in these studies, call 1-800-ROSWELL (1-800-767-9355). E-mail: askroswell@roswellpark.org
 

A Phase 1 Study of ADI-001 Anti-CD20 CAR-engineered Allogeneic Gamma-Delta T Cells in Adults with Autoimmune Disease (ADI-202300103)

Principal Investigator: Holtan, Shernan G

A Phase 2, Open-Label, Multicenter Study of BMS-986393, a GPRC5D-directed CAR T Cell Therapy in Adult Participants with Relapsed or Refractory Multiple Myeloma (QUINTESSENTIAL)

Principal Investigator: Malek, Ehsan

A Pragmatic Phase II Trial of Chemotherapy +/- Tocilizumab for Metastatic Triple Negative and ER-low Breast Cancers

Principal Investigator: Kabraji, Sheheryar K

A Phase 3 Randomized Double-blind Study of Adjuvant Pembrolizumab With or Without V940 in Participants With Resectable Stage II to IIIB (N2) NSCLC not Achieving pCR After Receiving Neoadjuvant Pembrolizumab With Platinum-based Doublet Chemotherapy …

Principal Investigator: Fitzgerald, Bailey

MM1OA-EA02: A Randomized Phase II Study of Venetoclax and HMA-based Therapies for the Treatment of Older and Unfit Adults with Newly Diagnosed FLT3-mutated Acute Myeloid Leukemia (AML): A MyeloMATCH Treatment Trial

Principal Investigator: Wang, Eunice S

MyeloMATCH - Master Screening and Reassessment Protocol (MSRP) for Tier Advancement in the NCI myeloMATCH Clinical Trials

Principal Investigator: Wang, Eunice S

MM1OA-S03: A Randomized Phase II Trial of ASTX727 and Venetoclax Compared with ASTX727, Venetoclax, and Enasidenib for Newly Diagnosed Older Adults with IDH2 Mutant Acute Myeloid Leukemia: A MyeloMATCH Substudy

Principal Investigator: Wang, Eunice S

MM1MDS-A01: A Randomized Phase II Trial of Enasidenib-Based Therapies Versus Cedazuridine-Decitabine in Higher-Risk IDH2-Mutated Myelodysplastic Syndrome: A MyeloMATCH Sub-Study

Principal Investigator: Wang, Eunice S

MM1YA-CTG01: A MEASURABLE RESIDUAL DISEASE (MRD) FOCUSED, PHASE II STUDY OF VENETOCLAX PLUS CHEMOTHERAPY FOR NEWLY DIAGNOSED YOUNGER PATIENTS WITH INTERMEDIATE RISK ACUTE MYELOID LEUKEMIA: A TIER 1 MYELOMATCH CLINICAL TRIAL

Principal Investigator: Wang, Eunice S

MM1YA-S01: A Randomized Phase II Study Comparing Cytarabine + Daunorubicin (7+3) vs (Daunorubicin and Cytarabine) Liposome, Cytarabine + Daunorubicin + Venetoclax and Azacitidine + Venetoclax in Patients Aged 59 or Younger Who Are Considered High Risk …

Principal Investigator: Wang, Eunice S

A Phase 1/1b Open-Label, Dose Escalation, First-in-Human Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Anti-leukemic Activity of the Orally Available CDC-Like Kinase (CLK) Inhibitor, BH-30236, in Adults with Relapsed or…

Principal Investigator: Wang, Eunice S

A032102: PRECISION DIAGNOSTICS IN PROSTATE CANCER TREATMENT (PREDICT)

Principal Investigator: Chatta, Gurkamal S

(ACNS1931) A Phase 3 Study of Selumetinib (NSC# 748727, IND# 77782) or Selumetinib in Combination with Vinblastine for non-NF1, non-TSC Patients with Recurrent or Progressive Low-Grade Gliomas (LGGs) Lacking BRAFV600E or IDH1 Mutations

Principal Investigator: Barth, Matthew J

A Phase II Trial of GT103 in Combination with Pembrolizumab in STK11 mutant Non-Small Cell Lung Cancer (NSCLC)

Principal Investigator: Yau, Edwin H

Phase 1b Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of AMG 193 alone or in Combination with other Therapies in Subjects with Advanced Thoracic Tumors with homozygous MTAP Deletion

Principal Investigator: Dy, Grace K

A phase 2, randomised, multi-centre, open label trial to evaluate the safety and efficacy of
intravesical nadofaragene firadenovec alone or in combination with chemotherapy
(gemcitabine and docetaxel) or immunotherapy (pembrolizumab) in subjects with…

Principal Investigator: Li, Qiang J

A PHASE 1, FIRST IN HUMAN, DOSE-ESCALATION STUDY OF TORL-3-600 IN PARTICIPANTS WITH ADVANCED CANCER

Principal Investigator: Fountzilas, Christos

(AREN2231) Risk Adapted Treatment of Unilateral Favorable Histology Wilms Tumors (FHWT)

Principal Investigator: Twist, Clare J

A Pilot, Single-Arm, Phase II Trial of Tamoxifen plus Pegylated Liposomal Doxorubicin in Patients with Metastatic Triple Negative Breast Cancer

Principal Investigator: Kabraji, Sheheryar K

A Phase 1/2, First-in-Human Study of the Menin-KMT2A (MLL1)Inhibitor Bleximenib in Participants with Acute Leukemia

Principal Investigator: Wang, Eunice S

Open label dose-escalation and dose-expansion study to evaluate the safety, expansion, persistence and clinical activity of UCART22 (allogeneic engineered T-cells expressing Anti-CD22 Chimeric Antigen Receptor) in patients with relapsed or refractory…

Principal Investigator: Wang, Eunice S

(S2414) A Randomized Phase III Trial INcorporating Pathologic Complete ReSponse in Participants with Early StaGe Non Small Cell Lung Cancer to Optimize ImmunotHerapy in the AdjuvanT Setting (INSIGHT)

Principal Investigator: Fitzgerald, Bailey

A Phase 1, Open-Label, Dose-Escalation Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of the Combination of CLBR00l, an Engineered Autologous T Cell Product, and ABBV-461, an Antibody-Based Biologic, in Subjects with…

Principal Investigator: Krishnamurthy, Anuradha

( I-SPY 2) Investigation of Serial Studies to Predict your Therapeutic Response with Imaging and Molecular Analysis 2

Principal Investigator: Levine, Ellis G

(AAML1831) A Phase 3 Randomized Trial for Patients with de novo AML Comparing Standard Therapy Including Gemtuzumab Ozogamicin (GO) to CPX-351 with GO, and the Addition of the FLT3 Inhibitor Gilteritinib for Patients with FLT3 Mutations

Principal Investigator: Twist, Clare J